According to the latest financial data, China Life Insurance (2628.HK) released its financial results for the first quarter of 2026 on April 29, 2026. Here is a summary of the key figures:
Key Financial Highlights
- Market Cap: 851.33B HKD.
- Earnings Announcement Date: April 29, 2026.
- Revenue (TTM): 342.09B CNY.
- Net Income (TTM, available to common shareholders): 144.78B CNY.
- Total Cash (MRQ): 2.18T CNY.
- Total Debt/Equity (MRQ): 45.08%.
- Earnings Per Share (TTM): 5.92 CNY.
- Dividend Information: A cash dividend of 0.618 HKD per share has been declared, with an ex-dividend date of June 30, 2026.
Financial Ratios Analysis
| Item | Value |
| Profit Margin | 42.32% |
| Return on Assets (TTM) | 1.50% |
| Return on Equity (TTM) | 25.48% |
| P/E Ratio (TTM) | 5.09 |
Regarding the financial condition and future outlook of China Life Insurance (2628.HK) for the first quarter of 2026, the summary is as follows:
Key Changes in Q1 2026
- Operational Highlights: The Value of New Business (NBV) increased by 75.5% year-on-year, far exceeding market expectations. This reflects the company’s successful transition toward long-term, installment-based products.
- Earnings Decline: Net profit attributable to shareholders was 19.505B CNY, a year-on-year decrease of 32.28%, primarily due to weak stock market performance and fluctuations in investment returns.
- Insurance Business: Total premiums grew 1.1% to 358.478B CNY. New premiums from long-term insurance reached 85.66B CNY, an increase of 29.9% year-on-year.
- Solvency: The core solvency adequacy ratio was 156.87%, up 28.1 percentage points from the beginning of the year. Capital levels remain secure, supporting business expansion and investment flexibility.
Outlook for Next Quarter
- Market Sentiment: Despite the decline in Q1 net profit, the strong performance of the NBV has led the market to generally hold a positive view on the company’s future valuation.
- Investment Strategy: Management will continue to optimize asset allocation, focusing on fixed-income products to ensure stable cash flows, while actively positioning in high-potential innovation areas such as AI and biomedicine to mitigate market volatility.
- Sales Channels: The company will maintain an omni-channel operating strategy, strengthening core agent channels while optimizing both value and scale for bancassurance, and accelerating digital transformation to enhance service experience.
EPS Forecast for the Coming Year
According to current comprehensive analyst forecasts, the EPS estimates for China Life Insurance are as follows (in CNY):
| Forecast Year | EPS Forecast Range (RMB) |
| 2026 | 4.06 – 4.75 |
| 2027 | 4.62 – 5.14 |
Note: The above EPS forecasts represent a consensus of analysts; actual performance will be influenced by future capital market volatility, changes in the interest rate environment, and the progress of insurance business sales.
Fundamental Analysis
- Strengths:
- Market Leadership: As a leader in China’s life insurance industry, its agency scale and market share provide a significant competitive moat.
- Business Transformation: Recent strong growth in the Value of New Business (NBV) demonstrates that the high-value policy sales strategy is working, indicating a long-term improvement in business structure.
- Attractive Valuation: The current Price-to-Earnings (P/E) ratio is only about 5x, placing it at a relative historical low, which is attractive for value investors.
- Risks:
- Capital Market Correlation: As an institutional insurer, its net profit is highly dependent on capital market performance. If the stock markets in China and Hong Kong continue to fluctuate, investment returns will remain under pressure.
- Interest Rate Environment: A low-interest-rate environment compresses the spread margins for life insurance companies (where liability costs exceed asset yields). It is important to monitor the effectiveness of its asset allocation.
Technical Analysis
- Trend Observation: After the fluctuations in early 2026, the stock price is showing a bottoming-out, sideways trend. Currently, the price is near major moving averages. Key resistance is in the 13.5 to 14.0 HKD range, while solid support is established at 11.5 HKD.
- Indicator Signals: The MACD indicator shows momentum is leveling off, and the RSI is in a neutral zone. The market is in a consolidation phase as it digests earnings expectations, lacking strong buying momentum for a breakout in the short term.
Summary of Analyst Views
Based on comprehensive reports from major investment banks and analysts (such as Goldman Sachs, J.P. Morgan, and HSBC), the consensus is as follows:
- Target Price Range: Market target prices are set between 14.8 and 17.5 HKD.
- Investment Rating: Most analysts maintain “Overweight” or “Buy” ratings, with the primary logic being that the transformation of business value is clear and the current stock price has already fully reflected market pessimism regarding weak stock market conditions.
Estimated Potential Upside and Downside
Based on the current market environment and fundamental data, we set a baseline reference price of 12.5 HKD:
| Scenario | Estimated Price Range (HKD) | Potential Change | Core Drivers |
| Optimistic | 15.5 – 17.0 | +24% to +36% | Strong rebound in China/HK markets, rising interest rates, continued hot sales of high-value policies |
| Neutral | 12.0 – 13.5 | -4% to +8% | Markets remain flat, stable business structure, stable dividend payouts |
| Pessimistic | 10.5 – 11.0 | -12% to -16% | Sharp decline in capital markets, significant losses in investment portfolios, widening negative spreads |
Expert Summary
China Life Insurance is currently in a phase of “defensive growth.” If you are a long-term value investor, the current low-valuation range offers allocation value, especially as it provides stable dividend returns while defending against market downside risks. I suggest a “staged deployment” strategy; you may consider adding to your position if the price tests the 11.5 HKD support level, and confirm a trend reversal if it breaks through the 14.0 HKD resistance level.
Please be aware that the above analysis does not constitute direct investment advice. It is recommended that you check your personal asset allocation goals before executing any trades.
Source:
- https://hk.finance.yahoo.com/quote/2628.HK/
- https://www.etnet.com.hk/www/eng/stocks/realtime/quote_profit.php?code=02628
- https://simplywall.st/stocks/hk/insurance/hkg-2628/china-life-insurance-shares/future
- https://www.bloomberg.com/quote/2628:HK
- https://www.reuters.com/markets/companies/2628.HK
- https://www.investing.com/equities/china-life-insurance-co-ltd
Back to China Life Insurance page